Anti-Mullerian Hormone Role in In Vitro Fertilization Outcome

Chiman Khudhur  Mawlood

doi:10.56056/

Authors

Chiman Khudhur Mawlood MBChB, MD (Obs. & Gyne), PhD (Reproductive Medicine), Lecturer at College of Medicine-Hawler Medical University-Erbil city-Kurdistan region/Iraq

DOI:

https://doi.org/10.56056/

Keywords:

Anti-mullerian hormone, Infertility, In vitro fertilization

Abstract

Background and objectives: The in vitro fertilization plays a significant role for human development in last decades. Anti-müllerian hormone level evaluation is indicator of ovarian reserve. The aim of this study was to assess the role of anti-müllerian hormone in assessing the quality of in vitro fertilization outcomes.

Methods: It was a retrospective study implemented at in vitro fertilization center of private hospital in Erbil city, Kurdistan region-Iraq in duration of one year from 1^st of October, 2022 to 30^th of September, 2023 on sample of 50 infertile women underwent in vitro fertilization. The biochemical pregnancy was diagnosed through serum recognition of human chorionic gonadotrophin, while the clinical pregnancy was diagnosed by ultrasonography. The in vitro fertilization outcome was assessed in relation to anti-mullerian hormone level and other variables like demographic and hormonal status.

Results: Biochemical pregnancy was positive in 80% of infertile women, while clinical pregnancy was positive in 72% of them; 24 women with ongoing pregnancy and 12 women ended with live birth pregnancy. Mean anti-mullerian hormone level was not significantly different in regard to clinical pregnancy outcome (p=0.4). The means of oocyte retrieved and embryo transferred were significantly higher among infertile women with positive clinical pregnancy (p?0.05). The anti-mullerian hormone level was positively correlated to the count of oocyte retrieved and embryo transferred.

Conclusions: The serum anti-mullerian hormone level is not a predictor for in vitro fertilization quality.

Downloads

Download data is not yet available.

References

1. Kuhnt AK, Passet-Wittig J. Families formed through assisted reproductive technology: Causes, experiences, and consequences in an international context. Reprod Biomed Soc Online 2022; 14:289-96.

2. Eskew AM, Jungheim ES. A History of developments to improve in vitro fertilization. Mo Med 2017; 114(3):156-9.

3. Teoh PJ, Maheshwari A. Low-cost in vitro fertilization: current insights. Int J Womens Health 2014; 6:817-27.

4. van Loendersloot LL, van Wely M, Limpens J, Bossuyt PM, Repping S, van der Veen F. Predictive factors in in vitro fertilization (IVF): a systematic review and meta-analysis. Hum Reprod Update 2010; 16(6):577-89.

5. Moolhuijsen LME, Visser JA. Anti-mullerian hormone and ovarian reserve: update on assessing ovarian function. J Clin Endocrinol Metab 2020; 105:3361-73.

6. Cui L, Qin Y, Gao X, Lu J, Geng L, Ding L, et al. Antimüllerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause. Fertil Steril 2016; 105(2):481-5. e1.

7. Jung S, Allen N, Arslan AA, Baglietto L, Barricarte A, Brinton LA, et al. Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts. Int J Cancer 2018; 142(2):262-70.

8. Kanakatti Shankar R, Dowlut-McElroy T, Dauber A, Gomez-Lobo V. Clinical utility of anti-mullerian hormone in pediatrics. J Clin Endocrinol Metab 2022; 107(2):309-23.

9. Shrikhande L, Shrikhande B, Shrikhande A. AMH and its clinical implications. J Obstet Gynaecol India 2020; 70(5):337-41.

10. Jiao X, Meng T, Zhai Y, Zhao L, Luo W, Liu P, et al. Ovarian reserve markers in premature ovarian insufficiency: Within Different Clinical Stages and Different Etiologies. Front Endocrinol 2021; 12:601752.

11. Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update 2015; 21(06):698–710.

12. Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. Am J Obstet Gynecol 2017; 217(02):129–40.

13. Umarsingh S, Adam JK, Krishna SBN. The relationship between anti-Mullerian hormone (AMH) levels and pregnancy outcomes in patients undergoing assisted reproductive techniques (ART). PeerJ 2020; 8: e10390.

14. Esteves SC, Alviggi C, Humaidan P, Fischer R, Andersen CY, Conforti A, et al. The POSEIDON Criteria and Its Measure of Success through the Eyes of Clinicians and Embryologists. Front Endocrinol (Lausanne) 2019; 10:814.

15. Yao L, Zhang W, Li H, Lin W. The role of serum AMH and FF AMH in predicting pregnancy outcome in the fresh cycle of IVF/ICSI: a meta-analysis. Int J Clin Exp Med 2015; 8:1755-67.

16. Anckaert E, Smitz J, Schiettecatte J, Klein BM, Arce JC. The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments. Hum Reprod 2012; 27:1829-39.

17. Goswami M, Nikolaou D. Is AMH Level, Independent of Age, a Predictor of Live Birth in IVF? J Hum Reprod Sci 2017; 10:24-30.

18. Vaiarelli A, Zacà C, Spadoni V, Cimadomo D, Conforti A, Alviggi C, et al. Clinical and laboratory key performance indicators in IVF: A consensus between the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR) and the Italian Society of Embryology, Reproduction and Research (SIERR). J Assist Reprod Genet 2023; 40(6):1479-94.

19. Murshid RM, Alaany R, Ammar OF. Epidemiological profile of infertile couples in Western Iraq. Int. J. Publ. Health sci 2024; 13 (1): 1-6.

20. Hussein MJ, Alalaf SK, Al-Tawil NG. Effect of maternal age on the ovarian reserve markers, and pregnancy outcome in a sample of Kurdish women in Erbil city. Zanco J Med Sci 2018; 22(1): 8-16. Available from: https://doi.org/10.15218/zjms.2018.002/

21. Wang CW, Kuo CY, Chen CH, Hsieh YH, Su EC. Predicting clinical pregnancy using clinical features and machine learning algorithms in in vitro fertilization. PLoS One 2022; 17(6): e0267554.

22. Smith ADAC, Tilling K, Nelson SM, Lawlor DA. Live-Birth Rate Associated with Repeat In Vitro Fertilization Treatment Cycles. JAMA 2015; 314(24):2654-62.

23. Pacheco A, Cruz M, Iglesias C, García-Velasco JA. Very low anti-müllerian hormone concentrations are not an independent predictor of embryo quality and pregnancy rate. Reprod Biomed Online 2018; 37(1):113-9.

24. Park HJ, Lyu SW, Seok HH, Yoon TK, Lee WS. Anti-Müllerian hormone levels as a predictor of clinical pregnancy in in vitro fertilization/intracytoplasmic sperm injection-embryo transfer cycles in patients over 40 years of age. Clin Exp Reprod Med 2015; 42(4):143-8.

25. Tokura Y, Yoshino O, Ogura-Nose S, Motoyama H, Harada M, Osuga Y, et al. The significance of serum anti-Müllerian hormone (AMH) levels in patients over age 40 in first IVF treatment. J Assist Reprod Genet 2013; 30(6):821-5.

26. Karkanaki A, Vosnakis C, Panidis D. The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology. Hormones (Athens) 2011; 10(2):95-103.

27. Pandian Z, Gibreel A, Bhattacharya S. In vitro fertilisation for unexplained subfertility. Cochrane Database Syst Rev 2015; 2015(11):CD003357.

28. Carosso AR, van Eekelen R, Revelli A, Canosa S, Mercaldo N, Stura I, et al. Expectant management before in vitro fertilization in women aged 39 or above and unexplained infertility does not decrease live birth rates compared to immediate treatment. Reprod Sci 2022; 29(4):1232-40.

29. Momeni M, Rahbar MH, Kovanci E. A meta-analysis of the relationship between endometrial thickness and outcome of in vitro fertilization cycles. J Hum Reprod Sci 2011; 4(3):130-7.

30. Ryan A, Wang S, Alvero R, Polotsky AJ. Prolonged gonadotropin stimulation for assisted reproductive technology cycles is associated with decreased pregnancy rates for all women except for women with polycystic ovary syndrome. J Assist Reprod Genet 2014; 31(7):837-42.

31. Wang Y, Zhang M, Shi H, Yi S, Li Q, Su Y, et al. Causes and Effects of Oocyte Retrieval Difficulties: A Retrospective Study of 10,624 Cycles. Front Endocrinol (Lausanne) 2022; 12:564344.

32. Wang P, Zhao C, Xu W, Jin X, Zhang S, Zhu H. The association between the number of oocytes retrieved and cumulative live birth rate in different female age strata. Sci Rep 2023; 13(1):14516.

33. Sun XY, Lan YZ, Liu S, Long XP, Mao XG, Liu L. Relationship Between Anti-Müllerian Hormone and In Vitro Fertilization-Embryo Transfer in Clinical Pregnancy. Front Endocrinol (Lausanne) 2020; 11:595448.